Impact of Glenosphere Size on Range of Motion in Female Patients Undergoing Reverse Shoulder Arthroplasty

Sponsor
Fondren Orthopedic Group L.L.P. (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04093804
Collaborator
(none)
120
1
2
59
2

Study Details

Study Description

Brief Summary

The purpose of this study is to perform a prospective randomized trial among female patients undergoing reverse shoulder arthroplasty (RSA) to determine if a larger glenosphere allows greater range of motion without an impact on complications.

Condition or Disease Intervention/Treatment Phase
  • Device: Glenosphere size for Reverse Shoulder Arthroplasty
N/A

Detailed Description

A current research debate is whether glenosphere size has a significant clinical impact on a patient's range of motion (ROM) following RSA. Some researchers have shown an association between increased glenosphere size and improved ROM, but no study has determined the absolute minimal motion differences that would be recognizable or beneficial by patients. This is mostly attributable to limitations such as small sample sizes as well as the fact that shoulder dynamics are multifactorial in nature. Most studies have shown an increased ROM with larger glenosphere sizes.1 Because smaller patients are often times female and receive smaller implants, female patients may be more susceptible to limited ROM. The purpose of this study is to determine if a larger glenosphere allows for greater ROM in female patients undergoing RSA.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This study is a randomized trial consisting of female patients undergoing reverse shoulder arthroplasty for rotator cuff tear arthropathy or a massive irreparable rotator cuff tear. The experimental group will receive a 36mm glenosphere and the control group will receive the standard 32mm glenosphere. All other conditions of the surgical procedure will be identical as well as the clinical follow-up.This study is a randomized trial consisting of female patients undergoing reverse shoulder arthroplasty for rotator cuff tear arthropathy or a massive irreparable rotator cuff tear. The experimental group will receive a 36mm glenosphere and the control group will receive the standard 32mm glenosphere. All other conditions of the surgical procedure will be identical as well as the clinical follow-up.
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Impact of Glenosphere Size on Range of Motion in Female Patients Undergoing Reverse Shoulder Arthroplasty
Anticipated Study Start Date :
Oct 1, 2019
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Sep 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: 32mm Glenosphere

The control group will receive the standard 32mm glenosphere.

Device: Glenosphere size for Reverse Shoulder Arthroplasty
Two randomized study groups will be formed with the consented patients (experimental and control). All patients will undergo reverse shoulder arthroplasty by the Principal Investigator. The experimental group patients will receive a 36mm glenosphere and the control group will receive a 32mm glenosphere. All other procedures during the surgery are identical between groups.

Experimental: 36mm Glenosphere

The experimental group will receive a 36mm glenosphere.

Device: Glenosphere size for Reverse Shoulder Arthroplasty
Two randomized study groups will be formed with the consented patients (experimental and control). All patients will undergo reverse shoulder arthroplasty by the Principal Investigator. The experimental group patients will receive a 36mm glenosphere and the control group will receive a 32mm glenosphere. All other procedures during the surgery are identical between groups.

Outcome Measures

Primary Outcome Measures

  1. Active range of motion [Change from baseline (pre-operative) to 2 years follow-up]

    Shoulder elevation, abduction, external rotation in abduction, and internal rotation

  2. Passive range of motion [Change from baseline (pre-operative) to 2 years follow-up]

    Shoulder elevation and external rotation

Secondary Outcome Measures

  1. American Shoulder and Elbow Surgeon (ASES) Shoulder Index [Change from baseline (pre-operative) to 2 years follow-up]

    Standard functional outcomes questionnaire following shoulder surgery, range 0 - 100 (highest function)

  2. Constant-Murley Shoulder Outcome score [Change from baseline (pre-operative) to 2 years follow-up]

    Standard functional outcomes questionnaire following shoulder surgery, range 0 - 100 (highest function)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Female sex

  • Diagnosis of rotator cuff tear arthropathy or a massive irreparable rotator cuff tear for which the patient has elected to undergo reverse shoulder arthroplasty

  • No history of prior shoulder arthroplasty

  • Consent to study participation by signing the informed consent and the Protected Health Information (PHI) form (Attachment B and C)

  • Ability to speak, read and write English

Exclusion Criteria:
  • Male sex

  • Any impairment that would prevent answering the surveys

  • No children or adolescents under the age of 18 years old

  • No prisoners, pregnant women, or mentally disabled persons

  • No Workers' Compensation cases

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fondren Orthopedic Group, L.L.P. Houston Texas United States 77030

Sponsors and Collaborators

  • Fondren Orthopedic Group L.L.P.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Fondren Orthopedic Group L.L.P.
ClinicalTrials.gov Identifier:
NCT04093804
Other Study ID Numbers:
  • TOH183
First Posted:
Sep 18, 2019
Last Update Posted:
Sep 18, 2019
Last Verified:
Sep 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 18, 2019